CTIX is a screaming buy. The Clinical Trials a
Post# of 72440
Posted On: 08/20/2015 4:25:26 PM
CTIX is a screaming buy.
The Clinical Trials are going full steam, two completed successfully. Brilacidin Phase 2b a HUGE success, and going to a high probability Phase 3!
Kevetrin is a lock for a successful Phase 1 Primary Outcome. Going to at least two new Phase 2 Clinical Trials. (Revised after today's PR, looks like there will be a Phase 2/3 also, and the ongoing Kevetrin trial at Harvard's Dana Farber is wrapping up soon)
Brilacidin-OM Phase 2 is recruiting at multiple sites. Worked great in the established hamster model, now we get to see how it works in humans.
Prurisol Phase 2 is recruiting at multiple sites. Worked great in the established mouse model, now we get to see how it works in humans.
Shares are at bargain basement levels because of bloggers full of falsehoods and innuendo.
Exact bottom share price? Depends on the buyers and sellers in the future. But the clinical trials are going great. Just look at the past PRs again.
The Clinical Trials are going full steam, two completed successfully. Brilacidin Phase 2b a HUGE success, and going to a high probability Phase 3!
Kevetrin is a lock for a successful Phase 1 Primary Outcome. Going to at least two new Phase 2 Clinical Trials. (Revised after today's PR, looks like there will be a Phase 2/3 also, and the ongoing Kevetrin trial at Harvard's Dana Farber is wrapping up soon)
Brilacidin-OM Phase 2 is recruiting at multiple sites. Worked great in the established hamster model, now we get to see how it works in humans.
Prurisol Phase 2 is recruiting at multiple sites. Worked great in the established mouse model, now we get to see how it works in humans.
Shares are at bargain basement levels because of bloggers full of falsehoods and innuendo.
Exact bottom share price? Depends on the buyers and sellers in the future. But the clinical trials are going great. Just look at the past PRs again.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼